Investors
Headquartered in Paris, Mifcare is a biotechnology company developing breakthrough anti-inflammatory therapeutics with a primary focus on pulmonary arterial hyprtension (PAH).
MIfcare’s most advanced product is orally-available small molecule MIF antagonist MFC1040 for the treatment of PAH. Mifcare believes that partnering with major players in the pharmaceutical or biotechnology industry will be key to bringing its drug candidates to market.
If you are evaluating Mifcare as a potential investment opportunity in biotechnology and need additional informations, please contact us.